On March 17, 2016 Dynavax Technologies Corporation (NASDAQ: DVAX) reported that it will present data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting next month in New Orleans, Louisiana (Press release, Dynavax Technologies, MAR 17, 2016, View Source [SID:1234509605]). The details for the poster presentations are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Date and Time: Monday, April 18, 2016, 1:00 p.m. – 5:00 p.m. EDT
Abstract Title: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial
Session Title: Phase I Clinical Trials 1
Abstract Control Number: 7361
Permanent Abstract Number: CT047
Location: Convention Center, Halls G-J, Poster Section 13
Poster Board Number: 3
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Monday, April 18, 2016, 1:00 p.m. – 5:00 p.m. EDT
Abstract Title: Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade
Session Title: Immune Checkpoints 1
Abstract Control Number: 4045
Permanent Abstract Number: 2322
Location: Convention Center, Halls G-J, Poster Section 26
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 18, 2016.
Date and Time: Wednesday April 20, 2016, 8:00 a.m. – 12:00 p.m. EDT
Abstract Title: Radiation potentiates systemic anti-tumor immunity unleashed by a novel TLR9 agonist (SD-101)
Session Title: Immune Modulation from Non-Immunotherapy and Antibodies: Clinical
Abstract Number: 4985
Location: Convention Center, Halls G-J, Poster Section 26
Poster Board Number: 9
Please click here for the full abstract. The poster presentation with updated data will be made available on or after April 20, 2016.
About SD-101
SD-101, the subject of AACR (Free AACR Whitepaper) abstracts CT047, 2322 and 4985, is Dynavax’s proprietary, second-generation, CpG-C class oligodeoxynucleotide TLR 9 agonist. SD-101 activates multiple anti-tumor mechanisms of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and induce high levels of Type I interferons and maturation of plasmacytoid dendritic cells and B cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.